As of September 2024, two FDA-approved drugs, Leqembi and Kisunla, have been introduced that may slow the progression of Alzheimer's disease in patients, demonstrating a reduction in mental decline by over 25%. Individual responses to these drugs can differ significantly; some patients may see more pronounced effects, while others may not benefit as much. NPR Science Correspondent Jon Hamilton highlights the experiences of two patients who have taken these medications, illustrating the variability in treatment outcomes. This development signals a hopeful advancement in Alzheimer's care, yet emphasizes the uniqueness of individual patient reactions.
Susan Bell plays with a fidget toy at her home as part of her physical therapy on September 16, 2024 in St. Charles, Mo. The toys help provide Susan with cognitive stimulation.
There are now two fully approved drugs on the market that can, sometimes, slow down the progression of Alzheimer's disease. Both have been shown to slow down the mental decline of Alzheimer's by more than 25%.
Collection
[
|
...
]